It’s official now, COPD is on the list with the other chronic conditions, so no worries about COPD off label prescriptions any longer with this one.  Actually though the other conditions it has been approved for are many times combined with COPD as well.  BD 


RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Dec 17, 2009 - Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Spiriva HandiHaler (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Spiriva HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with COPD, which includes chronic bronchitis, emphysema, or both.

FDA Approves Spiriva HandiHaler for the Reduction of COPD Exacerbations


Post a Comment

Google Analytics Alternative